It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We investigate a relatively underexplored component of the gut-immune axis by profiling the antibody response to gut phages using Phage Immunoprecipitation Sequencing (PhIP-Seq). To cover large antigenic spaces, we develop Dolphyn, a method that uses machine learning to select peptides from protein sets and compresses the proteome through epitope-stitching. Dolphyn compresses the size of a peptide library by 78% compared to traditional tiling, increasing the antibody-reactive peptides from 10% to 31%. We find that the immune system develops antibodies to human gut bacteria-infecting viruses, particularly E.coli-infecting Myoviridae. Cost-effective PhIP-Seq libraries designed with Dolphyn enable the assessment of a wider range of proteins in a single experiment, thus facilitating the study of the gut-immune axis.
Profiling antibody responses to vast antigenic spaces has been challenging using programmable phage display (PhIP-Seq). Here, authors develop a methodology for compressing large proteomic spaces and have discovered human antibodies targeting gut bacteria-infecting phages.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Johns Hopkins University, Department of Computer Science, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Institute of Cell Engineering, Division of Immunology, Department of Pathology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
2 Johns Hopkins University, Institute of Cell Engineering, Division of Immunology, Department of Pathology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
3 Harvard Medical School, Department of Genetics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Howard Hughes Medical Institute, Brigham and Women’s Hospital, Division of Genetics, Department of Medicine, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
4 University of Colorado Denver, Barbara Davis Center for Diabetes, Aurora, USA (GRID:grid.241116.1) (ISNI:0000 0001 0790 3411)
5 Clinical and Epidemiologic Sciences, FHI 360, Behavioral, Durham, USA (GRID:grid.245835.d) (ISNI:0000 0001 0300 5112)
6 Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, Jill Roberts Institute for Research in IBD, New York, USA (GRID:grid.471410.7) (ISNI:0000 0001 2179 7643)
7 University of Utah School of Medicine, Department of Pathology, Division of Microbiology and Immunology, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
8 Johns Hopkins University, Department of Biostatistics, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
9 Johns Hopkins University, Department of Computer Science, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)